StockData

Arcturus Therapeutics vs ProQR Therapeutics

ARCT and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARCT and PRQR compare

ProQR Therapeutics grew revenue faster over the last twelve months (11.4% versus −76.0% for Arcturus Therapeutics).

ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −318% at Arcturus Therapeutics.

Arcturus Therapeutics scores higher on the StockData Score (9 against 7 for ProQR Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARCTPRQR
Size and price
Market cap$227M–
Share price$7.97$1.15
Change, 1 year9.6%−47.0%
Change, 5 years−80.0%−84.0%
Beta (5Y)2.032.58
Employees11159
StockData Score
Total score9 (better)7
Valuation score2 (better)0
Growth score02 (better)
Performance score22
Health score5 (better)3
Dividend score00
Valuation
P/S7.7×–
P/B1.3×–
FCF yield−32.1%–
Fair value$8.83–
Margin of safety9.8%–
Growth
Revenue growth (TTM)−76.0%11.4% (better)
Revenue growth, 5Y average53.8%–
Profitability
Operating margin−348%−233% (better)
Net margin−318%−229% (better)
FCF margin−248% (better)−273%
Return on equity−46.3% (better)−57.4%
Return on invested capital−1084%–
Financial health
Debt / equity0.000.06 (better)
Current ratio5.88 (better)3.49
Altman Z-score−1.44–
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions87.9%57.6%
Held by insiders8.1%37.8%
Insider net buying, 12 months–$1.3M
Short interest, % of float20.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.